Avacta Group PLC has appointed Shaun Chilton as the Non-Executive Chairman, replacing Eliot Forster, who is stepping down from the Board. Chilton, who has been a Non-Executive Director at Avacta since June 2023, brings over 30 years of experience in leading and managing both private and public businesses in the biopharma sector. The company's Board of Directors has signaled ongoing plans for an evolution to meet the demands of being a clinical stage oncology company, as Avacta accelerates the clinical development of its pre|CISION™ platform.
The appointment of Chilton comes as part of the company's plans to support the clinical development of its pre|CISION™ platform and transition to a therapeutics-focused organization. Christina Coughlin, the newly appointed Chief Executive Officer, expressed her excitement about working with Chilton and focusing on the key goals and priorities for the company.
Chilton expressed his enthusiasm about the potential of the pre|CISION™ platform to transform cancer treatment and the opportunity to work closely with the management team and the wider Board. He also thanked Eliot Forster for his guidance and leadership. Avacta Group PLC is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company's two proprietary platforms, pre|CISION™ and Affimer®, are aimed at developing novel, highly targeted cancer drugs and broadening access to diagnostics.
The pre|CISION™ platform, in particular, is designed to reduce systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. Avacta's Board of Directors has indicated that further evolution of the Board membership is planned in the near future to support the company's transition to a therapeutics-focused organization.